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patients. Adherent patients had lower rate of depression (4.7% vs. 9.5%, P = 0.019), 
higher rate of previous DMD use (49.1% vs. 40.0%, P = 0.032), and higher baseline 
MS-related costs ($4757 vs. $4037, P < 0.001). After adjusting for differences in 
baseline characteristics, DMD adherent patients had lower occurrence of severe 
relapses (12.4% vs. 19.9%, P = 0.013) and lower total (direct and indirect) costs 
($14,095 vs. $16,638, P = 0.048). CONCLUSIONS: Over the two-year study period, 
DMD adherence was associated with signiﬁcantly fewer severe relapses and lower 
total medical costs.
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OBJECTIVES: To assess the contribution of the Zarit score, a measure of perceived 
caregiver burden in Alzheimer’s disease, to health related quality of life as measured 
by the physical and mental component scores of the SF-12 instrument and SF-6D 
health utilities. METHODS: A survey of Alzheimer caregivers was undertaken in the 
US in 2009 (n = 1,079). This survey captured both the characteristics of caregivers 
and the characteristics of the patient to whom the caregiver gave most attention. At 
the same time, caregivers were asked to complete the Zarit burden of care question-
naire and the SF-12 HRQoL instrument. To assess the impact of Zarit scores on 
HRQoL, linear regression (ordinary least squares) models were speciﬁed and estimated 
for the physical and mental component summary scores of the SF-12 and the health 
utility scores from the SF-6D. Independent variables included: caregiver and patient 
characteristics. RESULTS: Average PCS and MCS scores were 47.7 (STD 11.17) and 
42.5 (STD 11.93) respectively; utility score was 0.68 (STD 0.13). Zarit scores were 
distributed with 20.4% of respondents reporting a minimal or no burden, 37.7% a 
mild to moderate burden, 33.1% moderate to severe burden and 8.8% a severe 
burden. Overall16.3% were judged to have mild AD, 53.7% moderate and 30.0% 
severe. Zarit scores played the key role with their greatest impact on the MCS rather 
than the PCS dimensions of the SF-12. In the severe AD category the PCS deﬁcit is 
−5.65 (t = −4.23) compared to a deﬁcit of −17.94 (t = −14.09) for MCS. The corre-
sponding health utility deﬁcit is −0.19 (t = −13.15). Other key variables are caregiver 
age and gender, patient age and gender and living situation. CONCLUSIONS: Per-
ceived caregiver burden is associated primarily with deﬁcits on the mental component 
scores of the SF-12 and on SF-6D health utilities.
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OBJECTIVES: Botulinum Toxin Type-A (BoNTA) is approved for many therapeutic 
indications in Canada, including blepharospasm, 7th cranial nerve disorders, cervical 
dystonia, focal spasticity, cerebral palsy, and hyperhidrosis. Unfortunately, little is 
known about the impact of treatment on health utility. The objective of the ongoing 
national MOBILITY study is to measure the impact of BoNTA on health utility. 
METHODS: Phase IV prospective observational cohort study in patients receiving 
BoNTA for approved therapeutic indications in Canada. Physical component scores 
(PCS), and mental component scores (MCS) are derived from self-reported SF-12v2 
at baseline, week 4 and subsequent clinic visits. Health utility is then measured using 
the SF-6D scoring programme. In this interim analysis continuous data were analyzed 
by student’s t-test and dichotomous data by Chi-square test. RESULTS: To date 917 
patients have been enrolled at 40 clinical sites with a 94.5% retention rate. 69.7% of 
patients returned the week 4 survey and data from 608 individuals were included in 
the analysis (526 were receiving ongoing BOTOX® treatment at baseline; 82 were 
BoNTA-naïve). Signiﬁcant differences were detected in self-reported SF-6D scores 
between baseline and week 4 in the analysis of continuous (p = 0.05) and dichotomized 
data (p = 0.0001), and between baseline and week 4 in the analysis of continuous 
MCS data (p = 0.03). Among BoNTA-naïve patients, there was a statistically signiﬁ-
cant difference in SF-6D scores between baseline and week 4 (p = 0.03 for continuous 
data; p = 0.018 for dichotomized data). There were no statistical signiﬁcant changes 
in the SF-6D scores for patients receiving on-going treatment. CONCLUSIONS: This 
interim analysis from a large ongoing national study shows that signiﬁcant improve-
ments in health utility are obtained in patients receiving BoNTA for therapeutic indica-
tions. Health utility beneﬁt was most pronounced in BoNTA-naive patients as 
evidenced by week 4 MCS scores (the expected peak effect window). Further recruit-
ment and long term follow-up and analyses are ongoing.
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OBJECTIVES: To develop algorithms that convert disease-speciﬁc quality-of-life 
scores for the Headache Impact Test (HIT)-6 and the Migraine Speciﬁc Quality of 
Life, v. 2.1 (MSQ) Questionnaire to health-state utility values derived from the 
EuroQoL-5D (EQ-5D) in chronic migraineurs. METHODS: Data from a cross-sec-
tional multi-country study was used. Chronic migraineurs (ICHD-2 diagnosis of 
migraine and ≥15 headache days/month) completed a series of questions including the 
HIT-6 (n = 547), MSQ (n = 499), and EQ-5D. Subjects were randomly assigned to 
training and validation samples of equal size. Correlations between paired EQ-5D 
index scores and both HIT-6 scores and MSQ domain scores (Role-Restrictive [RR], 
Role-Preventative [RP], and Emotional-Function [EF]) were examined using Spearman 
correlation coefﬁcients. Regression models were constructed to predict EQ-5D utility 
values from the HIT-6 scores or the MSQ domain scores. Preferred algorithms were 
validated using the validation samples. RESULTS: Correlations between the EQ-5D 
index score and the HIT-6 and MSQ dimension scores were statistically signiﬁcant (p 
< 0.001) with correlation coefﬁcients of −0.33 (HIT-6), 0.44 (MSQ-RR), 0.46 (MSQ-
RP), and 0.30 (MSQ-EF). The preferred HIT-6 algorithm was a non-linear model 
which contained a quadratic term for HIT-6, and explained 34% of the variance in 
the training sample. The preferred MSQ algorithm was a linear model with covariates 
representing each domain, and explained 43% of the variance in the training sample. 
Both models also included covariates for age, gender, employment status, headache 
medication use, and comorbidities. In the validation analyses, no statistically signiﬁ-
cant difference was observed between the mean observed EQ-5D score and the mean 
EQ-5D score estimated using the preferred algorithms. CONCLUSIONS: The relation-
ship between the two disease-speciﬁc instruments and the EQ-5D are sufﬁciently 
robust to use regression equations to estimate EQ-5D utility values. These preferred 
models may be useful in estimating health-state utilities in trials of CM patients where 
no preference-based measure is present.
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OBJECTIVES: To evaluate the reliability and validity of the Brief Insomnia Question-
naire (BIQ), a fully-structured measure to assess insomnia based on DSM-IV-TR, 
ICD-10, and RDC criteria. METHODS: The AIS is a large (n = 10,094) epidemiologi-
cal survey of the prevalence and correlates of insomnia in a nationally representative 
sample of managed health care plan subscribers. Probability sub-samples of AIS 
respondents over-sampling BIQ cases completed either short-term test-retest interviews 
(n = 59) or clinical reappraisal interviews (n = 203) to assess BIQ reliability and 
validity. RESULTS: Test-retest correlations were .72–.95 for reports of frequency and 
.47–.94 for reports of severity of sleep problems (initiation, maintenance, non-restor-
ative sleep), .66–.88 for reports of daytime impairment/distress, and .62 for reported 
duration. Good individual-level concordance was found between diagnoses based on 
the BIQ and clinical interviews for meeting criteria in any of the three diagnostic 
systems, with area under the receiver operating characteristic curve (AUC, a measure 
of classiﬁcation accuracy not inﬂuenced by disorder prevalence) of .86 for dichoto-
mous classiﬁcations. AUC increased to .94 when symptom-level data were added to 
generate a continuous measure of predicted probability of clinical diagnosis. AUC was 
lower for dichotomous classiﬁcations based on RDC (.68) and ICD-10 (.70) than 
DSM-IV-TR (.83) criteria, but increased when symptom-level data were added to 
generate continuous measures of predicted probability of diagnoses (.92–.95). CON-
CLUSIONS: The results demonstrate that the BIQ can be used to obtain accurate 
estimates of prevalence and correlates of insomnia in the American Insomnia Survey.
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OBJECTIVES: Symptoms of Restless Legs Syndrome (RLS) typically worsen in the 
early evening and nighttime affecting patients’ quality and duration of sleep which 
can have next day sequelae detrimental to daytime performance. The present qualita-
tive research aimed to support the content validity of a new self-reported outcome 
measure to document the impact of disturbed sleep due to RLS on next day function-
ing. METHODS: An initial conceptual framework was developed based upon a review 
of the literature. The development of the Restless Legs Syndrome—Next Day Impact 
(RLS-NDI) questionnaire included: concept elicitation interviews with 20 clinician-
conﬁrmed idiopathic RLS patients in the US (aged 35–64); grounded theory data 
collection and analysis methods; achievement of saturation; and review by clinical and 
